Nkarta NKTX 深 沪
交易中 05-20 11:43:33 美东时间
2.78
+0.100
+3.73%
华盛通- 最 高2.805
- 今 开2.72
- 成交量 14.66万股
- 最 低 2.69
- 昨 收 2.68
- 总市值 1.99亿
- 52周最高 3.65
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 1.63
- 委 比 -32.32%
- 总股本 7154.54万
- 历史最高 79.16
- 量 比 0.61
- 振 幅 4.29%
- 历史最低 1.28
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
05-13 18:45
Nkarta Q1 EPS $(0.37), Inline
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
05-13 04:33
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta reported Q1 2026 financial results with a cash balance of $266.7 million, supporting operations into 2029. Enrollment continues in Ntrust-1 and Ntrust-2 trials at 4 billion cell dose levels. FDA agreement allows outpatient dosing and expansion to community settings. Initial clinical data expected in 2026. R&D expenses were $25.0 million, G&A expenses $5.9 million, resulting in a net loss of $27.8 million.
05-12 20:01
Nkarta rises on FDA agreement for amended trial protocol
Nkarta (NKTX) added ~13% on Thursday after the cell therapy developer said that the company reached an agreement with the U.S. FDA to change the protocol of a clinical program that allows outpatient d...
04-17 01:38
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Needham Maintains Buy on Nkarta, Raises Price Target to $11
Needham analyst Gil Blum maintains Nkarta (NASDAQ:NKTX) with a Buy and raises the price target from $10 to $11.
03-26 20:21
Nkarta Launches $100 Million At-the-Market Stock Offering
The latest update is out from Nkarta ( ($NKTX) ). On March 25, 2026, Nkarta, In...
03-26 18:41
